Last $18.90 USD
Change Today +0.10 / 0.53%
Volume 38.4K
CLDN On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 10:00 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

celladon corp (CLDN) Snapshot

Open
$18.80
Previous Close
$18.80
Day High
$18.96
Day Low
$18.31
52 Week High
12/29/14 - $20.85
52 Week Low
06/3/14 - $7.82
Market Cap
440.5M
Average Volume 10 Days
446.3K
EPS TTM
$-9.34
Shares Outstanding
23.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLADON CORP (CLDN)

Related News

No related news articles were found.

celladon corp (CLDN) Related Businessweek News

No Related Businessweek News Found

celladon corp (CLDN) Details

Celladon Corporation, a clinical-stage biotechnology company, focuses on developing treatments for heart failure, diabetes, and neurodegenerative diseases. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that results in inadequate pumping of the heart. Its MYDICAR product is developed to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company was founded in 2000 and is headquartered in San Diego, California.

26 Employees
Last Reported Date: 11/12/14
Founded in 2000

celladon corp (CLDN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $417.5K
Principal Financial & Accounting Officer and ...
Total Annual Compensation: $216.3K
Vice President of Corporate Development & Inv...
Total Annual Compensation: $190.4K
Vice President of Clinical Operations
Total Annual Compensation: $216.3K
Compensation as of Fiscal Year 2013.

celladon corp (CLDN) Key Developments

Celladon Corporation Conducts Initial Scale Up of Manufacturing Process for MYDICAR to Commercial Scale

Celladon Corporation announced that it has conducted initial scale up of its viral manufacturing process for MYDICAR (AAV1/SERCA2a) to commercial scale. The scale up of primary production and downstream processing development to 2,000 liters was undertaken together with Lonza, in its facility in Houston, Texas.

Celladon Corporation(NasdaqGM:CLDN) added to NASDAQ Biotechnology Index

Celladon Corporation will be added to the NASDAQ Biotechnology Index.

Celladon Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 08:20 AM

Celladon Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 08:20 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Kristina Zsebo, CEO.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLDN:US $18.90 USD +0.10

CLDN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLDN.
View Industry Companies
 

Industry Analysis

CLDN

Industry Average

Valuation CLDN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLADON CORP, please visit www.celladon.net. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.